I'm hoping Acadia is actively reviewing the data they're generating from the Daybue rollout to try and identify any correlations between their patients details and the severity of GI issues. I don't know enough of the history of the drug development but they would have some PK data and an understanding of the potential for drug-drug interactions that may help them enhance the sophistication of their recommendations to current and future patients.
Katelin’s Turn is HERE!!!, page-96
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3104 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.01pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable